<DOC>
	<DOC>NCT00935064</DOC>
	<brief_summary>This study will assess the effect of direct renin inhibition on nerve function in persons with diabetes using a double-blind, placebo-controlled randomized trial involving two treatment arms (i.e., [1] 30 participants enrolled and randomized to 300 mg of Aliskiren; [2] 30 participants enrolled and randomized to placebo).</brief_summary>
	<brief_title>The Effect of Renin Inhibition on Nerve Function in Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Individuals &gt;18 years old with type 1 or type 2 diabetes mellitus. Individuals currently taking the maximum dose of an ACE inhibitor or an ARB. Individuals with a history of a MI, percutaneous coronary interventions, coronary artery bypass graft (CABG) surgery, acute coronary syndromes, recent/on going atrial fibrillation, frequent atrial arrhythmias, frequent ventricular arrhythmias, or acute myocardial ischemia changes. Individuals whose treatment dosage changes 2 months prior to the study for antihypertensive and antidiabetes medications, and the following medications that may affect the ANS: antituberculosis drugs, nitrofurantoin, metronidazole, chloramphenicol, perhexiline maleate, amiodarone, clofibrate, tricyclic antidepressants, phenytoin, barbiturates, neuroleptic, antiparkinsonism drugs, and nitrated drugs. Pregnant or lactating females. Individuals with impaired renal function (i.e., creatinine &gt;1.5 mg/dl), a history of dialysis, nephritic syndrome or renovascular hypertension. Individuals with potassium levels within 0.5 mmol/L of the upper limit of normal (i.e., hyperkalemia).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Diabetes</keyword>
</DOC>